Mr. Tom Dehaene, Vice-Governor Internationalization
Ms. Thu Jennifer Ngo-Anh, SciSpacE Team Leader at the European Space Agency
Mr. Olivier Henry, Program Manager Life Sciences and Medical Device Technologies of imec
Mrs. Ann Schevenels, Vice-Governor Economy
Mr. Jan Schrooten
‘The serendipitous discovery of novel microsatellite instability biomarkers’
Prof. Dr. Diether Lambrechts, PhD, director of VIB-KU Leuven Center for Cancer Biology (CCB)
Prof. Dr. Tom Lenaerts of ULB and VUB
Being the European hot spot for life sciences innovation, Flanders has identified personalized medicine as an innovation priority within its smart specialization strategy and aims to support translation of ideas to the patient that are enabled by such things as biomarker discovery and validation, data gathering and analytics, digital modelling and prediction of medical interventions, smart implantables, advanced manufacturing techniques for personalized drugs or prosthesis, artificially intelligent diagnosis and smart logistics. Flanders is taking the lead in personalized medicine by fueling collaborative innovation within the Flemish bio-, nano- and med-tech sector to capture the unique opportunities in the transformation of personalized medicine.
As Wallonia emerges as a world class biotech and medtech hub, the region wants to accelerate innovation. With life sciences being a key growth sector, Wallonia enhances the development of the biopharmaceutical and medtech ecosystem by bringing together all the actors involved in innovation in this area. In line with the principles of smart specialization, Wallonia focuses on six technological target areas for which the Walloon region has a critical mass of global players: biopharmacy, cell therapy, radiation applied to health, medical devices and in vitro diagnostics, biomanufacturing and data-driven science.
The space sector is evolving rapidly and is ready to reach out to other important economic sectors. This is also the case for the Flemish space industry. By combining the leading position of Flanders in biotechnology with the knowhow of the Flemish space actors in microgravity research, the session will examine how cross-innovation between both can lead to innovative solutions, products and proofs of concept. A particular emphasis will be put on the available options for research in the International Space Station (ISS) and on how technology transfer for diagnosis can be realized.
Within the pharmaceutical and medical world personalized patient care is a key trend in Europe and on an international level. The potential is huge, for patients and sector alike. Partnerships are essential to realize the potential of personalized medicine. Hence, on different levels multi-stakeholder collaborations are emerging that build on vivid ecosystems combining biomedical, technological and data driven expertise.
Further strengthening these ecosystems, based on regional and complementary smart specialization, will enable even more in-depth cross-over collaborations and as such build long-term roadmaps across ecosystems that will assist in materializing the potential of PM in our regions, in Europe and in space.